Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Drug Price Transparency Gains Traction

Executive Summary

A Web site created through a pilot program has helped instill greater confidence among 340B entities on the accuracy of the drug prices they pay, and a bill pending in Congress would ensure price transparency

You may also be interested in...



“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding

A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues

“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding

A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues

Medicaid AMPs May Include More PBM Discounts, If CMS Can Figure Out How

CMS wants to include a broader array of pharmacy benefit manager price concessions in calculating Medicaid average manufacturer prices for reimbursing outpatient prescription drugs

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel